Logo: to the web site of Uppsala University

uu.sePublications from Uppsala University
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
The value of post-operative chemotherapy after chemoradiotherapy in patients with high-risk locally advanced rectal cancerdresults from the RAPIDO trial
Univ Groningen, Univ Med Ctr Groningen, Dept Med Oncol, Hanzepl 1,Postbus 30-001, NL-9700 RB Groningen, Netherlands..
Univ Groningen, Univ Med Ctr Groningen, Dept Med Oncol, Hanzepl 1,Postbus 30-001, NL-9700 RB Groningen, Netherlands..
Karolinska Univ Hosp, Dept Surg, Stockholm, Sweden..
Leiden Univ, Dept Med Stat & Bioinformat, Med Ctr, Leiden, Netherlands..
Show others and affiliations
2023 (English)In: ESMO Open, E-ISSN 2059-7029, Vol. 8, no 2, article id 101158Article in journal (Refereed) Published
Abstract [en]

Background: Pre-operative chemoradiotherapy (CRT) rather than radiotherapy (RT) has resulted in fewer locoregional recurrences (LRRs), but no decrease in distant metastasis (DM) rate for patients with locally advanced rectal cancer (LARC). In many countries, patients receive post-operative chemotherapy (pCT) to improve oncological outcomes. We investigated the value of pCT after pre-operative CRT in the RAPIDO trial.

Patients and methods: Patients were randomised between experimental (short-course RT, chemotherapy and surgery) and standard-of-care treatment (CRT, surgery and pCT depending on hospital policy). In this substudy, we compared curatively resected patients from the standard-of-care group who received pCT (pCT+ group) with those who did not (pCT- group). Subsequently, patients from the pCT+ group who received at least 75% of the prescribed chemotherapy cycles (pCT >75% group) were compared with patients who did not receive pCT (pCT-/- group). By propensity score stratification (PSS), we adjusted for the following unbalanced confounders: age, clinical extramural vascular invasion, distance to the anal verge, ypT stage, ypN stage, residual tumour, serious adverse event (SAE) and/or readmission within 6 weeks after surgery and SAE related to pre-operative CRT. Cumulative probability of disease-free survival (DFS), DM, LRR and overall survival (OS) was analysed by Cox regression.

Results: In total, 396/452 patients had a curative resection. The number of patients in the pCT+, pCT >75%, pCT- and pCT-/- groups was 184, 112, 154 and 149, respectively. The PSS-adjusted analyses for all endpoints demonstrated hazard ratios between approximately 0.7 and 0.8 (pCT+ versus pCT-), and 0.5 and 0.8 (pCT >75% versus pCT-/-). However, all 95% confidence intervals included 1.

Conclusions: These data suggest a benefit of pCT after pre-operative CRT for patients with high-risk LARC, with approximately 20%-25% improvement in DFS and OS and 20%-25% risk reductions in DM and LRR. Compliance with pCT additionally reduces or improves all endpoints by 10%-20%. However, differences are not statistically significant.

Place, publisher, year, edition, pages
ELSEVIER Elsevier, 2023. Vol. 8, no 2, article id 101158
Keywords [en]
locally advanced rectal cancer, post-operative chemotherapy, oncological outcomes, propensity score stratification, adjuvant chemotherapy
National Category
Cancer and Oncology Surgery
Identifiers
URN: urn:nbn:se:uu:diva-506985DOI: 10.1016/j.esmoop.2023.101158ISI: 001005120500001PubMedID: 36871393OAI: oai:DiVA.org:uu-506985DiVA, id: diva2:1778805
Funder
Swedish Cancer SocietySwedish Research Council, K2014-99X-22481-01-3Available from: 2023-07-03 Created: 2023-07-03 Last updated: 2024-12-03Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMed

Authority records

Nygren, PeterGlimelius, Bengt

Search in DiVA

By author/editor
Nygren, PeterVerbiene, I.Glimelius, Bengt
By organisation
Cancer Pharmacology and Computational MedicineScience for Life Laboratory, SciLifeLabCancer precision medicineDepartment of Immunology, Genetics and Pathology
In the same journal
ESMO Open
Cancer and OncologySurgery

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 53 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf